InvestorsHub Logo
Followers 0
Posts 484
Boards Moderated 0
Alias Born 10/10/2014

Re: staccani post# 1383

Saturday, 09/30/2017 3:36:03 PM

Saturday, September 30, 2017 3:36:03 PM

Post# of 2099
Trial will be stopped if mOS improved by 50%+. Optune's trial was stopped with less significant improvement in mOS:

In the per-protocol population, patients treated with TTFields plus temozolomide demonstrated a statistically significant increase in OS, a powered secondary endpoint, compared to temozolomide alone (median OS 20.5 months versus 15.6 months, hazard ratio=0.64, p=0.0042). In the intent-to-treat population, the median OS was 19.6 months versus 16.6 months, respectively, hazard ratio=0.74 (p=0.0329).

http://www.businesswire.com/news/home/20151215005370/en/Journal-American-Medical-Association-JAMA-Publishes-Pivotal
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VBLT News